Trials / Completed
CompletedNCT01207011
Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer
A Randomised, Open-Label Phase 3 Trial Comparing Amrubicin Versus Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure of First-Line Chemotherapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 202 (actual)
- Sponsor
- Sumitomo Pharma Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The study is to evaluate the effect of amrubicin (AMR) compared to docetaxel (DOC) in the treatment of non-small cell lung cancer (NSCLC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amrubicin hydrocloride | AMR was administered i.v. by 35mg/m2 at day 1, 2 and 3 followed by 3 week rest as 1 course. |
| DRUG | Docetaxel | DOC was administered i.v. by 60mg/m2 at day 1 followed by 3 week rest as 1 course. |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2014-06-01
- Completion
- 2014-06-01
- First posted
- 2010-09-22
- Last updated
- 2022-04-12
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01207011. Inclusion in this directory is not an endorsement.